|
Abbreviated name: AM
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Adrenomedullin is 52 amino acid peptide which is mainly expressed in endothelial and smooth muscle cells. It acts as a vasodilatory peptide and it is known to regulate endothelial barrier function and vascular tone. Evidence from animal models indicates that it is a key player in the development of sepsis-associated hemodynamic and microcirculatory disorders.
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Adrenomed Ag are developing an anti-adrenomedullin monoclonal therapeutic (adrecizumab, HAM8101) for the treatment or prevention of septic shock and associated systemic inflammation [3,8]. Results from a first-in-human trial of adrecizumab in healthy subjects and during experimental human endotoxaemia (induced by endotoxin bolus administration) were reported in June 2018 by Geven et al. [4] (see clinical trial NCT03083171). Adrecizumab was found to be safe and well tolerated in human subjects, in the absence and presence of systemic inflammation, and the endotoxin-induced flu-like symptoms resolved more rapidly in response to adrecizumab administration. |
